Clinical Trial Update: Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial update reports results comparing four versus six cycles of cyclophosphamide/doxorubicin or paclitaxel in adjuvant breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Alliance for Clinical Trials in Oncology | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2017-05-18